Literature DB >> 33036782

Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the "halo sign" and "string sign".

Joseph R Habib1, Benedict Kinny-Köster1, Floortje van Oosten1, Ammar A Javed1, John L Cameron1, Kelly J Lafaro1, Richard A Burkhart1, William R Burns1, Jin He1, Elizabeth D Thompson2, Elliot K Fishman3, Christopher L Wolfgang4.   

Abstract

Most patients diagnosed with pancreatic cancer are classified as nonoperative candidates based on the contemporary guidelines of resectability. The advent of more potent control of systemic disease using neoadjuvant chemotherapy has enabled more aggressive operative interventions. In our multidisciplinary practice, patients with Stage III, locally advanced pancreatic cancer and superior mesenteric artery (SMA) encasement are now carefully triaged with high quality, preoperative imaging to determine if they can be considered candidates for operative resection with periadventitial dissection of the SMA. Patients displaying a "halo sign," where the encased SMA remains fully patent and free from arterial invasion, are now candidates for SMA periadventitial dissection. This procedure involves the surgical stripping of the infiltrated neurolymphatic tissue off the SMA leaving behind a bare "skeletonized artery." Alternatively, the "string sign" involving the SMA confers a more likely case of arterial invasion, where a complete oncologic resection cannot be achieved successfully. This method of patient selection in case of SMA involvement abandons the traditional metrics of circumferential degrees of the arterial encasement to guide surgical decisions. Our institutional approach has allowed us to meaningfully expand our operative methods of resection with the potential for improved longitudinal outcomes to pancreatic cancer patients who were deprived historically from the more effective and possibly curative treatment.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33036782     DOI: 10.1016/j.surg.2020.08.031

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Time for a More Holistic Approach to Peri-Pancreatoduodenectomy Care.

Authors:  Joseph R Habib; Jin He
Journal:  Ann Surg Oncol       Date:  2021-04-02       Impact factor: 5.344

2.  Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer.

Authors:  Georgios Gemenetzis; Alex B Blair; Minako Nagai; William R Burns; Christopher L Wolfgang; Jin He; Vincent P Groot; Ding Ding; Ammar A Javed; Richard A Burkhart; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; John L Cameron; Amol Narang; Daniel Laheru; Kelly Lafaro; Joseph M Herman; Lei Zheng
Journal:  Ann Surg Oncol       Date:  2021-08-27       Impact factor: 5.344

3.  Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.

Authors:  Sami Shoucair; Joseph R Habib; Ning Pu; Benedict Kinny-Köster; A Floortje van Ooston; Ammar A Javed; Kelly J Lafaro; Jin He; Christopher L Wolfgang; Jun Yu
Journal:  Ann Surg Oncol       Date:  2021-11-18       Impact factor: 5.344

4.  Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): prospective pilot study.

Authors:  Thomas F Stoop; Eran van Veldhuisen; L Bengt van Rijssen; Remy Klaassen; Oliver J Gurney-Champion; Ignace H de Hingh; Olivier R Busch; Hanneke W M van Laarhoven; Krijn P van Lienden; Jaap Stoker; Johanna W Wilmink; C Yung Nio; Aart J Nederveen; Marc R W Engelbrecht; Marc G Besselink
Journal:  Langenbecks Arch Surg       Date:  2022-10-15       Impact factor: 2.895

5.  The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience.

Authors:  Ammar A Javed; Joseph R Habib; Benedict Kinny-Köster; Mary Hodgin; Lindsay Parish; Dea Cunningham; Amy Hacker-Prietz; Richard A Burkhart; William R Burns; Christopher R Shubert; John L Cameron; Atif Zaheer; Linda C H Chu; Satomi Kawamoto; Elizabeth D Thompson; Eun J Shin; Amol Narang; Lei Zheng; Daniel A Laheru; Ralph H Hruban; Jin He; Christopher L Wolfgang; Elliot K Fishman; Kelly Lafaro
Journal:  Curr Probl Diagn Radiol       Date:  2022-05-25

Review 6.  Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)-basis and current status.

Authors:  Anant Ramaswamy; Sujay Srinivas; Vikram Chaudhari; Prabhat Bhargava; Manish Bhandare; Shailesh V Shrikhande; Vikas Ostwal
Journal:  Ecancermedicalscience       Date:  2022-03-24

Review 7.  Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy.

Authors:  Danko Mikulic; Anna Mrzljak
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.